Literature DB >> 26718506

MicroRNA-200a mediates nasopharyngeal carcinoma cell proliferation through the activation of nuclear factor-κB.

Zhuliang Shi1, Zhiqiang Hu1, Delu Chen1, Jie Huang1, Jie Fan1, Subo Zhou1, Xin Wang1, Jiandao Hu2, Fei Huang3.   

Abstract

In nasopharyngeal carcinoma (NPC), the nuclear factor-κB (NF-κB) signaling pathway is highly active. The constitutive activation of NF-κB prompts malignant cell proliferation, and microRNAs are considered an important mediator in regulating the NF-κB signaling pathway. The current study investigated the effect of microRNA-200a (miR-200a) on NF-κB activation. Reverse transcription-quantitative polymerase chain reaction was used to quantify the relative level of miR-200a in NPC tissue samples and CNE2 cells. An MTT assay was used to investigate the effect of miR-200a on cell proliferation. To investigate the activation of NF-κB, western blotting was used to measure the protein levels of NF-κB and its downstream targets. To identify the target genes of miR-200a, a luciferase reporter assay was used. The current study demonstrated that miR-200a was upregulated in NPC tissue samples and cell lines. Overexpression of miR-200a resulted in the proliferation of CNE2 cells. Western blot analysis indicated that the protein levels of p65 increased when CNE2 cells were transfected with miR-200a mimics. Additionally, the downstream targets of miR-200a were upregulated, including vascular cell adhesion molecule, intercellular adhesion molecule and monocyte chemoattractant protein-1. The luciferase assay indicated that IκBα was the target gene of miR-200a. In conclusion, miR-200a was demonstrated to enhance NPC cell proliferation by activating the NF-κB signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26718506     DOI: 10.3892/mmr.2015.4738

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  7 in total

1.  Correlation analyses revealed global microRNA-mRNA expression associations in human peripheral blood mononuclear cells.

Authors:  Lan Wang; Jiang Zhu; Fei-Yan Deng; Long-Fei Wu; Xing-Bo Mo; Xiao-Wei Zhu; Wei Xia; Fang-Fei Xie; Pei He; Peng-Fei Bing; Ying-Hua Qiu; Xiang Lin; Xin Lu; Lei Zhang; Neng-Jun Yi; Yong-Hong Zhang; Shu-Feng Lei
Journal:  Mol Genet Genomics       Date:  2017-09-06       Impact factor: 3.291

Review 2.  Role of MicroRNA-141 in the Aging Musculoskeletal System: A Current Overview.

Authors:  Babatunde Fariyike; Quante Singleton; Monte Hunter; William D Hill; Carlos M Isales; Mark W Hamrick; Sadanand Fulzele
Journal:  Mech Ageing Dev       Date:  2018-12-07       Impact factor: 5.432

3.  MicroRNA-200a inhibits cell growth and metastasis by targeting Foxa2 in hepatocellular carcinoma.

Authors:  Shu-Ying Chen; De-Ning Ma; Qiu-Dan Chen; Jing-Jun Zhang; Yue-Ru Tian; Zhi-Cheng Wang; Hao Cai; Yong Lin; Hui-Chuan Sun
Journal:  J Cancer       Date:  2017-02-25       Impact factor: 4.207

Review 4.  Aging, Melatonin, and the Pro- and Anti-Inflammatory Networks.

Authors:  Rüdiger Hardeland
Journal:  Int J Mol Sci       Date:  2019-03-11       Impact factor: 5.923

Review 5.  Role of the NFκB-signaling pathway in cancer.

Authors:  Longzheng Xia; Shiming Tan; Yujuan Zhou; Jingguan Lin; Heran Wang; Linda Oyang; Yutong Tian; Lu Liu; Min Su; Hui Wang; Deliang Cao; Qianjin Liao
Journal:  Onco Targets Ther       Date:  2018-04-11       Impact factor: 4.147

6.  MiR-200a Regulates Nasopharyngeal Carcinoma Cell Migration and Invasion by Targeting MYH10.

Authors:  Wenya Liu; Tonghui Cai; Lingjun Li; Hui Chen; Ruichao Chen; Minfen Zhang; Wei Zhang; Li Zhao; Hanzhen Xiong; Ping Qin; Xingcheng Gao; Qingping Jiang
Journal:  J Cancer       Date:  2020-03-04       Impact factor: 4.207

7.  [ARTICLE WITHDRAWN] Long Noncoding RNA TUNAR Represses Growth, Migration, and Invasion of Human Glioma Cells Through Regulating miR-200a and Rac1.

Authors:  Jinhua Dai; Jianbo Ma; Bixia Yu; Zhankun Zhu; Yanqin Hu
Journal:  Oncol Res       Date:  2018-03-14       Impact factor: 5.574

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.